Analysts Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) PT at $48.67

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has earned an average recommendation of “Moderate Buy” from the thirteen analysts that are covering the stock, MarketBeat.com reports. Four analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $48.67.

A number of equities analysts have issued reports on KYMR shares. Wells Fargo & Company increased their price target on Kymera Therapeutics from $30.00 to $38.00 and gave the company an “equal weight” rating in a research note on Monday, August 12th. Leerink Partnrs raised Kymera Therapeutics to a “strong-buy” rating in a report on Monday, September 9th. Oppenheimer reissued an “outperform” rating and issued a $52.00 price target on shares of Kymera Therapeutics in a report on Wednesday, July 10th. B. Riley raised their price objective on shares of Kymera Therapeutics from $31.00 to $36.00 and gave the company a “neutral” rating in a research report on Tuesday, July 9th. Finally, Leerink Partners reiterated an “outperform” rating and issued a $60.00 target price on shares of Kymera Therapeutics in a report on Monday, September 9th.

Insider Activity at Kymera Therapeutics

In other Kymera Therapeutics news, Director Bruce Booth sold 453,960 shares of Kymera Therapeutics stock in a transaction that occurred on Tuesday, July 9th. The shares were sold at an average price of $38.21, for a total transaction of $17,345,811.60. Following the transaction, the director now directly owns 723,246 shares in the company, valued at approximately $27,635,229.66. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other Kymera Therapeutics news, Director Bruce Booth sold 453,960 shares of the firm’s stock in a transaction dated Tuesday, July 9th. The stock was sold at an average price of $38.21, for a total transaction of $17,345,811.60. Following the completion of the sale, the director now directly owns 723,246 shares in the company, valued at approximately $27,635,229.66. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Jared Gollob sold 23,145 shares of Kymera Therapeutics stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $45.81, for a total value of $1,060,272.45. Following the transaction, the insider now directly owns 95,470 shares in the company, valued at approximately $4,373,480.70. The disclosure for this sale can be found here. In the last 90 days, insiders sold 495,605 shares of company stock worth $19,303,364. 15.82% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Kymera Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. increased its stake in shares of Kymera Therapeutics by 1.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 306,692 shares of the company’s stock worth $7,808,000 after acquiring an additional 4,951 shares during the last quarter. Norges Bank acquired a new position in Kymera Therapeutics in the 4th quarter worth about $12,834,000. UBS Group AG lifted its holdings in shares of Kymera Therapeutics by 84.6% during the 4th quarter. UBS Group AG now owns 300,463 shares of the company’s stock valued at $7,650,000 after buying an additional 137,704 shares during the last quarter. Trexquant Investment LP acquired a new stake in shares of Kymera Therapeutics during the 4th quarter valued at about $5,183,000. Finally, Quest Partners LLC acquired a new position in Kymera Therapeutics in the fourth quarter worth approximately $78,000.

Kymera Therapeutics Stock Performance

Shares of KYMR opened at $49.47 on Friday. Kymera Therapeutics has a one year low of $9.60 and a one year high of $53.27. The stock’s fifty day moving average is $45.56 and its 200-day moving average is $39.25. The firm has a market capitalization of $3.05 billion, a price-to-earnings ratio of -20.85 and a beta of 2.22.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Wednesday, August 7th. The company reported ($0.58) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.10. The firm had revenue of $25.60 million for the quarter, compared to analysts’ expectations of $12.55 million. Kymera Therapeutics had a negative net margin of 178.27% and a negative return on equity of 28.88%. Kymera Therapeutics’s quarterly revenue was up 55.2% on a year-over-year basis. During the same quarter last year, the company earned ($0.67) EPS. Analysts forecast that Kymera Therapeutics will post -2.87 EPS for the current fiscal year.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.